Breaking News
Get 40% Off 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

Mabwell Shanghai Bioscience Co Ltd (688062)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
34.90 -1.00    -2.79%
08:00:01 - Closed. Currency in CNY ( Disclaimer )
Type:  Equity
Market:  China
ISIN:  CNE100005RD2 
  • Volume: 3,066,773
  • Bid/Ask: 34.85 / 34.90
  • Day's Range: 34.40 - 36.19
Mabwell Shanghai Bioscience 34.90 -1.00 -2.79%

Mabwell Shanghai Bioscience Co Ltd Company Profile

 
Get an in-depth profile of Mabwell Shanghai Bioscience Co Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

1451

Equity Type

ORD

Mabwell (Shanghai) Bioscience Co., Ltd., a biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of biological products in China and internationally. The company offers its products for auto-immune, oncology, ophthalmologic, and infectious diseases, as well as metabolic disorders, etc. It offers JUNMAIKANG, an autoimmune Adalimumab injection. The company’s oncology products pipeline includes 9MW2821 and 6MW3211, which are in phase II of clinical trial; 9MW2921, 9MW3811, and 7MW3711, which are in phase I clinical trials; 9MW0321; and 8MW0511, which is in phase III clinical trial. It also develops autoimmune products, such as 9MW1911 and 9MW3811, which are in phase 1 clinical trial; metabolic products comprising MAILISHU and 9MW3011; ophthalmology candidates, including 9MW0813 and 9MW0211 that are in phase III clinical trial; and 9MW1411, an infectious product candidate. The company was founded in 2017 and is based in Shanghai, China.

Contact Information

Address Building 2 Room 105, No. 230 Cailun Road
China (Shanghai) Pilot Free Trade Zone Shanghai, 201210
China
Phone 86 21 5833 2260
Fax 86 21 5858 5793

Top Executives

Name Age Since Title
Chunshan Tang 54 2020 Chairman of the Board
Qian Zhao 53 2020 Independent Director
Bailing Li 70 2020 Independent Director
Ning Xie 62 2020 Director
Qing Xu 60 2020 Independent Director
Yue Yin 41 2020 Supervisor
Xianghong Huang 45 2020 Employee Representative Supervisor
Jian Chu 57 2020 Chairman of the Supervisory Board
Yongqi Guo 42 2020 Director
Huiguo Hu 47 2020 Deputy GM, Secretary of the Board of Directors & Director
Datao Liu 52 2020 Chairman, CEO & GM
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

688062 Comments

Write your thoughts about Mabwell Shanghai Bioscience Co Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email